- •Preface
- •Contents
- •Contributors
- •1: Living with Diabetic Retinopathy: The Patient’s View
- •My Patient Experience
- •Others’ Experiences
- •Photos of the Meaning of Diabetes
- •References
- •2: Diabetic Retinopathy Screening: Progress or Lack of Progress
- •Definitions of Screening for Diabetic Retinopathy
- •Studies Reporting the Prevalence of Diabetic Retinopathy
- •Reports on Blindness and Visual Impairment
- •Is There Evidence That Treatment for Sight-Threatening Diabetic Retinopathy Is Effective and Agreed Universally?
- •The Evidence That Diabetic Retinopathy Can Be Prevented or the Rate of Deterioration Reduced by Improved Control of Blood Glucose, Blood Pressure and Lipid Levels, and by Giving Up Smoking
- •The Evidence that Laser Treatment Is Effective
- •The Evidence That Vitrectomy for More Advanced Disease Is Effective
- •Progress of Lack of Progress in Screening for Diabetic Retinopathy in Different Parts of the World
- •References
- •3: Functional/Neural Mapping Discoveries in the Diabetic Retina: Advancing Clinical Care with the Multifocal ERG
- •Introduction
- •The Diabetes Epidemic
- •Current Treatment Focus
- •Vasculopathy and Neuropathy of the Retina
- •The Early Efforts
- •Some Breakthroughs
- •Predictive Models of Visible Retinopathy Onset at Specific Locations
- •How Is the mfERG Measured and What is it Measuring?
- •Where Are These Neural Signals Generated in the Retina?
- •Some Key Results
- •Adolescents and Adult Diabetes
- •Type 1 vs. Type 2: Differences in Retinal Function
- •References
- •4: Corneal Diabetic Neuropathy
- •Introduction
- •Corneal Confocal Microscopy
- •Corneal Nerves and Diabetes
- •Conclusion
- •References
- •5: Clinical Phenotypes of Diabetic Retinopathy
- •Natural History
- •MA Formation and Disappearance Rates
- •Alteration of the Blood–Retinal Barrier
- •Retinal Capillary Closure
- •Multimodal Macula Mapping
- •Clinical Retinopathy Phenotypes
- •Relevance for Clinical Trial Design
- •Relevance for Clinical Management
- •Targeted Treatments
- •References
- •6: Visual Psychophysics in Diabetic Retinopathy
- •Introduction
- •Visual Acuity
- •Color Vision
- •Contrast Sensitivity
- •Macular Recovery Function (Nyctometry)
- •Perimetry
- •Microperimetry (Fundus-Related Perimetry)
- •Conclusion
- •References
- •7: Mechanisms of Blood–Retinal Barrier Breakdown in Diabetic Retinopathy
- •The Protective Barriers of the Retina
- •The Inner and the Outer BRB
- •Inflammation and BRB Permeability
- •Leukocyte Mediators of Vascular Leakage
- •Other Mediators of Leukocyte Recruitment in DR
- •Structural Compromise of the BRB
- •Vascular Endothelial Growth Factor
- •Anti-VEGF Properties of Natriuretic Peptides
- •Proposed Model of BRB Breakdown in DR
- •Key Role of AZ in VEGF-Induced Leakage
- •Azurocidin Inhibition Prevents Diabetic Retinal Vascular Leakage
- •References
- •8: Molecular Regulation of Endothelial Cell Tight Junctions and the Blood-Retinal Barrier
- •The Blood-Retinal Barrier
- •The Retinal Vascular Barrier
- •The Junctional Complex
- •ZO Proteins
- •Claudins
- •Junctional Adhesion Molecules
- •Occludin and Tricellulin
- •Vascular Permeability in Diabetic Retinopathy
- •VEGF-Induced Regulation of Endothelial Permeability
- •Occludin Phosphorylation and Permeability
- •Protein Kinase C in Regulation of Barrier Properties
- •Conclusions
- •References
- •9: Capillary Degeneration in Diabetic Retinopathy
- •Vascular Nonperfusion in Diabetes: Mechanisms
- •Molecular Causes of Capillary Degeneration
- •Unexplained Aspects of Diabetes-Induced Degeneration of Retinal Capillaries
- •What Is the Relation Between the Retinal Vasculature and Neuronal Retina Structure and Function in Diabetes?
- •Conclusion
- •References
- •10: Proteases in Diabetic Retinopathy
- •Proteases in Retinal Vasculature
- •Extracellular Proteases
- •Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Matrix Metalloproteinases
- •Endogenous Inhibitors of Proteases
- •Tissue Inhibitors of Metalloproteinases (TIMPs)
- •Plasminogen Activator Inhibitors (PAI)
- •Proteases in Retinal Neovascularization
- •Tissue Inhibitor of Matrix Metalloproteinases in Retinal Neovascularization
- •Inhibition of Retinal Angiogenesis by MMP Inhibitors
- •Inhibition of Retinal Angiogenesis by Inhibitors of the uPA/uPAR System
- •Proteases in Diabetic Macular Edema
- •Conclusion
- •References
- •11: Proteomics in the Vitreous of Diabetic Retinopathy Patients
- •Introduction
- •Vitreous Anatomy
- •A Candidate Approach
- •Proteomic Approaches
- •Vitreous Acquisition
- •Sample Pre-Fractionation
- •Mass Spectrometry
- •Spectral Analysis
- •Data Analysis
- •The Vitreous Proteome
- •2-DE-Based Proteomics
- •1-DE-Based Proteomics
- •Summary and Conclusions
- •References
- •12: Neurodegeneration in Diabetic Retinopathy
- •Introduction
- •Histological Evidence
- •Early Pathology Studies
- •Histological Evidence of Apoptosis
- •Gross Morphological Changes in the Retina
- •Reductions in Numbers of Surviving Amacrine Cells
- •Retinal Ganglion Cell Loss
- •Abnormalities in Ganglion Cell Morphology
- •Centrifugal Axon Abnormalities
- •Nerve Fiber Layer Thickness
- •Biochemical Evidence of Neurodegeneration and Cell Death
- •Functional Evidence of Neurodegenerative Changes
- •Electrophysiological Evidence for Neurodegeneration
- •Optic Nerve Retrograde Transport
- •Other Changes in Visual Function
- •Summary and Conclusions
- •References
- •13: Glucose-Induced Cellular Signaling in Diabetic Retinopathy
- •Introduction
- •Cellular Targets in DR
- •Endothelial Cell (EC) Dysfunction
- •Endothelial-Pericyte Interactions
- •Endothelial-Matrix Interactions
- •Signaling Mechanisms in DR
- •Altered Vasoactive Factors
- •Alteration of Metabolic Pathways
- •Polyol Pathway
- •Hexosamine Pathway
- •Protein Kinase C Pathway
- •Activation of Other Protein Kinases
- •Mitogen-Activated Protein Kinase (MAPK)
- •Increased Oxidative Stress
- •Protein Glycation
- •Aberrant Expression of Growth Factors
- •Transcription Factors
- •Transcription Regulators
- •Concluding Remarks
- •References
- •Introduction
- •The Growth-Hormone/Insulin-Like Growth Factor Pathway in Proliferative Retinopathies
- •Proliferative Diabetic Retinopathy (PDR)
- •Retinopathy of Prematurity (ROP)
- •Animal Models of Proliferative Retinopathies
- •IGFBP-3 as a Regulator of the Growth-Hormone/ Insulin-Like Growth Factor Pathway
- •Conclusion
- •References
- •15: Neurotrophic Factors in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Neurotrophic Factors
- •Neurotrophins and Others
- •Nerve Growth Factor
- •Glial-Cell-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Anti-angiogenic Neurotrophic Factors
- •Pigment-Epithelium-Derived Factor
- •SERPINA3K
- •Brain-Derived Neurotrophic Factor
- •Fibroblast Growth Factors
- •Insulin and Insulin-Like Growth Factor 1
- •Erythropoietin
- •Vascular Endothelial Growth Factor
- •Neurotrophic Factors and the Future of DR Research
- •References
- •16: The Role of CTGF in Diabetic Retinopathy
- •Introduction
- •ECM Remodeling and Wound Healing Mechanisms in Diabetic Retinopathy
- •ECM Remodeling in PCDR
- •Wound Healing Mechanisms in PDR
- •CTGF Structure and Function
- •CTGF in the Eye
- •CTGF in Ocular Fibrosis
- •CTGF in Ocular Angiogenesis
- •CTGF in Diabetic Retinopathy
- •CTGF in BL Thickening in PCDR
- •AGEs and CTGF in BL Thickening in PCDR
- •Role of VEGF in BL Thickening
- •BL Thickening in Diabetic CTGF-Knockout Mice
- •CTGF in PDR
- •Role of CTGF and VEGF in the “Angiofibrotic Switch” in PDR
- •Conclusions
- •References
- •17: Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema
- •Introduction
- •Pathogenesis of DME and Current Standard of Care
- •Ranibizumab for DME
- •Pegaptanib for DME
- •Bevacizumab for DME
- •VEGF Trap-Eye for DME
- •Other Considerations in the Management of DME
- •Combination Treatment for DME
- •DME and Quality of Life
- •Conclusions
- •References
- •18: Neurodegeneration, Neuropeptides, and Diabetic Retinopathy
- •Introduction
- •Neuropeptides Involved in the Pathogenesis of DR
- •Glutamate
- •Angiotensin II
- •Pigment Epithelial-Derived Factor
- •Somatostatin
- •Erythropoietin
- •Docosahexaenoic Acid and Neuroprotectin D1
- •Brain-Derived Neurotrophic Factor
- •Glial Cell Line-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Adrenomedullin
- •Concluding Remarks and Therapeutic Implications
- •References
- •19: Glial Cell–Derived Cytokines and Vascular Integrity in Diabetic Retinopathy
- •Introduction
- •The BRB Functional Unit Composed of Glial and Endothelial Cells
- •Tight Junctions Between Endothelial Cells Are Substantial Barrier of the BRB
- •Major Cytokines Derived from Glial Cells Affecting Tight Junctions of the BRB
- •VEGF
- •GDNF
- •APKAP12
- •A Possible Treatment of the Retinopathy with Retinoic Acid Analogues
- •Conclusion
- •References
- •20: Impact of Islet Cell Transplantation on Diabetic Retinopathy in Type 1 Diabetes
- •Introduction
- •What Are the Benefits and Risks of Reducing Blood Glucose?
- •On Average, 3 Years Was Required to Demonstrate the Beneficial Effect of Intensive Treatment
- •The Earlier in the Course of Diabetes That Intensive Therapy Is Initiated, Even Before the Onset of Retinopathy, the Greater the Long-Term Benefits
- •Risk Reduction in the Primary Prevention Cohort
- •Risk Reduction in the Secondary Prevention Cohort
- •There Was No Glycemic Threshold Regarding Progression of Retinopathy
- •Diabetic Ketoacidosis (DKA)
- •Efforts to Normalize Blood Glucose Are Associated with Weight Gain in People with Type 1 Diabetes
- •Connecting Peptide (C-Peptide) Responders Have Less Risk of Progression of Retinopathy
- •Effects of Improved Control on Retinopathy Were Sustained in the Long-Term
- •Quality of Life Measure
- •“Metabolic Memory”: A Phenomenon Producing a Long-Term Beneficial Influence of Early Metabolic Control on Clinical Outcomes
- •Need for a More Physiologic Glycemic Control Regimen
- •Effect of Intensive Insulin Therapy on Hypoglycemia Counterregulation
- •b Cell Function
- •Whole Pancreas Transplantation
- •Effect of SPK Transplantation on Diabetic Retinopathy
- •Islet Cell Transplantation
- •Adverse Effects of Chronic Immunosuppression
- •Effect of Islet Cell Transplantation on Retinopathy
- •References
- •Index
Clinical Phenotypes of Diabetic Retinopathy |
59 |
It appears that it is possible to use MA turnover computed from noninvasive color fundus photographs as a biomarker to identify eyes/patients at risk of progression to CSME.
ALTERATION OF THE BLOOD–RETINAL BARRIER
Fluorescein angiography confirmed most of what was known of the initial pathological picture of diabetic retinopathy and showed in the initial stages of the disease focal leaks of fluorescein, demonstrating, in a clinical setting, the existence of focal breakdowns of the BRB.
In 1975, vitreous fluorometry, a clinical quantitative method for the study of the BRB, was introduced by our group [6], showing that an alteration of the BRB could be detected and measured in some diabetic eyes presenting clinically normal fundi. These results were confirmed by Waltman et al. [9] and demonstrated that breakdown of the BRB plays an important initiating role in the development of the diabetic retinopathy.
One major limitation of the available commercial instrumentation for vitreous fluorometry was associated with the fact that the permeability of the BRB is measured as an average over the posterior pole. Accurate mapping of localized changes in the permeability of the BRB would be beneficial for early diagnosis, to explain the natural history of retinal disease, and to predict its effect on visual acuity.
We have recently developed a new method of retinal leakage mapping, the retinal leakage analyzer (RLA), which is capable of measuring localized changes in fluorescein leakage across the BRB while simultaneously imaging the retina (Fig. 3). The instrument is based on a confocal scanning laser ophthalmoscope that was modified into a confocal scanning laser fluorometer [25]. Two types of information are obtained simultaneously, distribution of fluorescein concentration (retina and vitreous) and
Fig. 3. Macula from a patient with diabetes type 2. Fluorescein angiography obtained by scanning laser ophthalmoscope (left). Retinal leakage analyzer (RLA) blood–retinal barrier (BRB) permeability map (RLmap) in a false color-code map (right).
60 |
Cunha-Vaz et al. |
morphology of the eye fundus. This simultaneous acquisition is crucial because it allows a direct correlation to be established between the maps of permeability and the morphological information.
RETINAL CAPILLARY CLOSURE
Retinal ischemia due to vascular closure develops relatively early in the course of diabetic retinopathy and is attributed to changes in vascular autoregulation and microthrombosis formation. Retinal blood flow changes are considered to lead to the development of poor perfusion facilitating microthrombosis formation [19].
Alterations in retinal blood flow have been identified in the different stages of the progression of retinopathy, but a major problem associated with these measurements is their technical complexity and variability. Our observations indicate that in some diabetic eyes, even before the development of visible retinopathy, there is (probably due to local factors) a marked increase in retinal capillary blood flow with maximal utilization of the retinal capillary net, whereas other eyes do not show this circulatory response, suggesting individual variations in the response to the altered metabolic status. This increase in retinal blood flow may contribute to localize endothelial damage and establish the appropriate conditions for microthrombosis formation.
NEURONAL AND GLIAL CELL CHANGES: RETINAL
THICKNESS MEASUREMENTS
We have stated previously that the simplest paradigm to explain increased capillary permeability and the advent of capillary closure centers on vascular endothelial damage. There are, however, a number of reports showing changes in the neuronal and glial cells of the retina in diabetes very early in the course of the disease [26]. This is clearly of major potential importance, and it may indicate at least a contributory role in the development of the microangiopathy.
Recent evidence suggests that retinal glial and Muller cells, in particular, are affected early in the course of both experimental and human diabetes.
Retinal edema is a frequent alteration occurring in the initial stages of diabetic retinal disease. As the disease progresses, it may cause CSME, one of the two major complications of disease associated with loss of vision. Based on WESDR data, it was estimated (as of 1993) that of approximately 7,800,000 people with diabetes, about 84,000 North Americans would develop proliferative retinopathy and about 95,000 would develop sight loss from macular edema over a 10-year period [11, 12].
Edema of the retina is any increase of water of the retinal tissue resulting in an increase in its volume, i.e., because of the structural organization of the retina, an increase in its thickness.
This increase in water content of the retinal tissue may be initially intracellular or extracellular. In the first case, also called cytotoxic edema, there is an alteration of the cellular ionic exchanges with an excess of Na+ inside the cell. In the second case, also called vasogenic edema, there is predominantly extracellular accumulation of fluid directly associated with the alteration of the BRB [27].
Clinical Phenotypes of Diabetic Retinopathy |
61 |
Fig. 4. Multimodal macula mapping of an eye with mild NPDR showing localized increases in leakage and retinal thickness. The background represents the leakage using a false color code. Units are × 10−7 cm/s (left). The gray areas represent increased retinal thickness (shown in white dots on the left image) (right).
It is now possible to objectively measure retinal thickness. Optical coherence tomography (OCT, Carl Zeiss Meditec, Dublin, CA, USA) is a powerful tool for the objective assessment of macular edema.
Measurements of retinal thickness show that localized areas of retinal edema are a frequent finding in the diabetic retina in the initial stages of NPDR in subjects with diabetes type 2 and allow to follow its progression to CSME.
MULTIMODAL MACULA MAPPING
The initial changes occurring in the diabetic retina involve the macula, and an alteration of the macula will, sooner or later, affect visual acuity.
There are a variety of diagnostic tools and techniques to examine the macular region and to obtain information on its structure and function. The different methods available offer different perspectives and fragmentary information. It has been our objective, in recent years, to combine different methodologies and to obtain maps of the alterations occurring in the macular region of the retina (Fig. 4).
Our research group has been developing methods to combine and integrate data from fundus photography, angiographic images (scanning laser ophthalmoscope–fluorescein angiography), maps of fluorescein leakage into the vitreous (scanning laser ophthalmo- scope–retinal leakage analyzer), and maps of retinal thickness of the macular area to achieve multimodal macula mapping [25, 28, 29].
CLINICAL RETINOPATHY PHENOTYPES
It is well recognized that duration of diabetes and level of metabolic control are important risk factors for development of diabetic retinopathy.
However, these risk factors do not explain the great variability that characterizes the evolution and rate of progression of the retinopathy in different diabetic individuals. There is clearly great individual variation in the course of diabetic retinopathy.
62 |
Cunha-Vaz et al. |
There are many diabetic patients who after many years with diabetes never develop sight-threatening retinal changes and maintain good visual acuity. There are also other patients that after only a few years of diabetes show a retinopathy that progresses rapidly developing one of the two major complications.
To characterize the clinical picture and progression of the retinal changes in the initial stages of NPDR, we performed a prospective 3-year follow-up study of the macular region, in 14 patients with type 2 diabetes mellitus and mild nonproliferative retinopathy, using multimodal macula mapping combining data from fundus photography, fluorescein angiography, retinal leakage analysis, and retinal thickness measurements [30].
In a span of 3 years, eyes with minimal changes at the start of the study (levels 20 and 35 of ETDRS-Wisconsin grading) were followed at 6-month intervals in order to monitor progression of the retinal changes.
The most frequent alterations observed were, by decreasing order of frequency MA, leaking sites on the RLA and areas of increased retinal thickness.
Increased rates of MA formation were found in eyes that showed more MA at baseline and higher values of BRB permeability during the study.
RLA-leaking sites were a very frequent finding and reached very high BRB permeability values in some eyes. These sites of alteration of the BRB, well identified in RLA maps, maintained, in most cases, the same location on successive examinations, but their BRB permeability values fluctuated greatly between examinations, indicating reversibility of this alteration.
There was, in general, a correlation between the BRB permeability values and the changes in HbA1C levels occurring in each patient. This correlation was particularly clear when looking at eyes that showed, at some time during the follow-up period, BRB permeability values within the normal range. A return to normal levels of BRB permeability was, in this study and in each patient, always associated with a stabilization or decrease in HbA1C values.
Areas of increased retinal thickness were another frequent finding in these eyes. They were present in every eye at some time during the follow-up and were absent, at baseline, in only 2 of the 14 eyes. This confirms previous observations by our group [25] and by others [31]. However, the areas of increased retinal thickness varied in their location over subsequent examinations and did not correlate with changes in HbA1C levels. They may represent a delayed response in time to other changes occurring in the retina, such as increased leakage [25]. They certainly represent in most cases zones of extracellular edema, an interpretation supported by the frequent shift observed in their location in subsequent examinations.
Multimodal imaging of the macula made apparent three major evolving patterns occurring during the follow-up period of 3 years: Pattern A includes eyes with a slow rate of MA formation, relatively little abnormal fluorescein leakage, and a normal FAZ. This group appears to represent eyes presenting slowly progressing retinal disease. Pattern B includes eyes with persistently high leakage values, indicating an important alteration of the BRB, high rates of MA formation, and a normal FAZ. All these features suggest a more rapid and progressive form of the disease. This group appears to identify a “wet” form of diabetic retinopathy. Pattern C includes eyes with high rates of MA formation and disappearance, variable leakage, and an abnormal FAZ. This group is less
Clinical Phenotypes of Diabetic Retinopathy |
63 |
Fig. 5. Multimodal images from three different patients, at yearly intervals, showing for each visit the foveal avascular zone (FAZ) contour, RLA results, and retinal thickness analyzer results. (A) Pattern A. Note the little amount of retinal leakage over the four represented visits and the normal FAZ contour. This patient showed a slow rate of microaneurysm formation. (B) Pattern B. Note the high retinal leakage showing a certain degree of reversibility and the normal FAZ contour. This patient showed a high rate of microaneurysm accumulation over the 3-year follow-up period. (C) Pattern C. Note the reversible retinal leakage and the development of an abnormal FAZ contour. This patient showed a high rate of microaneurysm formation.
well characterized considering the small number of eyes that showed an abnormal FAZ. It may be that abnormalities of the FAZ may occur as a late development of groups A and B or progress rapidly as a specific “ischemic” form (Fig. 5).
We have now extended our observations after following for 2 years 59 patients with diabetes type 2 and mild NPDR. In this larger study, these three different phenotypes were again clearly identified. The discriminative markers of these phenotypes were MA formation and disappearance rates, degree of fluorescein leakage, and signs of capillary closure in the capillaries surrounding the FAZ [23].
It must be realized that levels of hyperglycemia and duration of diabetes, i.e., exposure to hyperglycemia, are expected to influence the evolution and rate of progression tentatively classified in these three major patterns.
If diabetic retinopathy is a multifactorial disease—in the sense that different factors or different pathways may predominate in different groups of cases with diabetic retinopathy—then it is crucial that these differences and the different phenotypes are identified.
